MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,708.00
-12.00 (-0.70%)
Last updated: Oct 30, 2025, 11:14 AM KST
-0.70%
Market Cap67.48B
Revenue (ttm)12.16B
Net Income (ttm)-12.87B
Shares Out39.05M
EPS (ttm)-360.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume33,709
Average Volume260,281
Open1,707.00
Previous Close1,720.00
Day's Range1,691.00 - 1,735.00
52-Week Range999.00 - 2,250.00
Beta1.36
RSI51.43
Earnings DateNov 11, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.